Cigna Group reported first‑quarter 2026 revenue of $68.49 billion, up 5% from $65.5 billion in Q1 2025, and net income of $1.65 billion, a 27% increase from $1.3 billion a year earlier. Diluted earnings per share rose to $6.26, while adjusted EPS climbed to $7.79, beating the consensus estimate of $7.61 by $0.18 (2.4%). The beat was driven by disciplined cost control and a favorable mix shift toward higher‑margin specialty‑care services within Evernorth Health Services, which generated $58.4 billion in adjusted revenue and $1.47 billion in pre‑tax adjusted income, up 9% and 2% respectively year‑over‑year.
The company’s adjusted operating income increased 12% to $2.06 billion, reflecting a 2% rise in operating margin from 10.2% to 10.4%. Evernorth Health Services was the primary growth engine, while Cigna Healthcare contributed $11.5 billion in adjusted revenue and $1.51 billion in pre‑tax adjusted income, achieving a 13.2% pre‑tax margin. Pharmacy Benefit Services, however, saw a 28% decline in pre‑tax adjusted income due to lower contributions from large client relationships, offsetting some of the upside in Evernorth’s specialty‑care volume growth.
Management raised its full‑year 2026 adjusted EPS outlook to at least $30.35, up from the prior $30.33. The modest lift signals confidence in continued demand for Evernorth’s health‑services platform and the improving margin profile of Cigna Healthcare, while acknowledging the need to manage the transition away from legacy business lines. The guidance increase also reflects the company’s expectation of sustained cost discipline and the anticipated impact of the HCSC transaction on its medical‑care ratio.
CEO David M. Cordani highlighted the company’s focus on “improving how people experience health care” through innovation and technology, noting that disciplined execution and portfolio shaping drove the quarter’s results. CFO Ann Dennison emphasized the 16% year‑over‑year EPS growth and the decision to raise the full‑year outlook. COO Brian Evanko announced plans to exit the individual exchange business by year‑end and to initiate a strategic review of eviCore, underscoring a shift toward core growth platforms.
Investors reacted cautiously, with some concerns about valuation and the exit of legacy business lines. The market’s muted response reflects broader sentiment, but the earnings beat and raised guidance reinforce confidence in Cigna’s strategic direction.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.